Anticipated updates in key breast cancer clinical trials at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting underscore “the importance of continued innovation in breast cancer therapy,” according to Reshma L. Mahtani, DO.
Ahead of the meeting, CancerNetwork® spoke with Mahtani, chief of breast medical oncology at Miami Cancer Institute of Baptist Health South Florida, about the presentations with the potential to shift the treatment paradigm across different types of breast cancer. Of note, Mahtani highlighted the phase 3 DESTINY-Breast09 trial (NCT04784715), which is assessing fam-trastuzumab deruxtecan-nxki (T-DXd; Enhertu) plus pertuzumab (Perjeta); the phase 3 ASCENT-04/KEYNOTE-D19 study (NCT05382286), which is evaluating sacituzumab govitecan-hziy (Trodelvy) plus pembrolizumab (Keytruda); and the phase 3 VERITAC-2 trial (NCT05654623), which is investigating the novel proteolysis targeting chimera (PROTAC) vepdegestrant, as the developments to look out for at the meeting.
